CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/ma...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2019-01-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0906.htm |
| _version_ | 1818337345443725312 |
|---|---|
| author | ZHANG Baihong YUE Hongyun |
| author_facet | ZHANG Baihong YUE Hongyun |
| author_sort | ZHANG Baihong |
| collection | DOAJ |
| description | Cyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, immune therapy, molecular targeted agents and the other therapeutics could overcome its resistance and improve clinical benefits. CDK4/6 inhibitors-based combinational therapeutics provides a promising window for human cancer treatment. |
| first_indexed | 2024-12-13T14:53:44Z |
| format | Article |
| id | doaj.art-5706a13b62504d228bd19266acf48efe |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-13T14:53:44Z |
| publishDate | 2019-01-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-5706a13b62504d228bd19266acf48efe2022-12-21T23:41:17ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782019-01-01461727510.3971/j.issn.1000-8578.2019.18.09068578.2019.18.0906CDK4/6 Inhibitors-based Combinational Therapy for Human CancersZHANG Baihong0YUE Hongyun1Department of Oncology, People's Liberation Army 940 Hospital, Lanzhou 730050, ChinaDepartment of Ophthalmology, People's Liberation Army 940 Hospital, Lanzhou 730050, ChinaCyclin-dependent kinases (CDKs) inhibitors have been approved in the combination with hormone-based therapy for advanced breast cancer. In addition to endocrine therapy, the combinations of CDK4/6 inhibitors with epidermal growth factor receptor (EGFR) inhibitors, phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, immune therapy, molecular targeted agents and the other therapeutics could overcome its resistance and improve clinical benefits. CDK4/6 inhibitors-based combinational therapeutics provides a promising window for human cancer treatment.http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0906.htmneoplasmstherapeuticscdk4/6 inhibitors |
| spellingShingle | ZHANG Baihong YUE Hongyun CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers Zhongliu Fangzhi Yanjiu neoplasms therapeutics cdk4/6 inhibitors |
| title | CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers |
| title_full | CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers |
| title_fullStr | CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers |
| title_full_unstemmed | CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers |
| title_short | CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers |
| title_sort | cdk4 6 inhibitors based combinational therapy for human cancers |
| topic | neoplasms therapeutics cdk4/6 inhibitors |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0906.htm |
| work_keys_str_mv | AT zhangbaihong cdk46inhibitorsbasedcombinationaltherapyforhumancancers AT yuehongyun cdk46inhibitorsbasedcombinationaltherapyforhumancancers |